US courts disagree on generic drug exclusivity

被引：0

|

作者：

Ken Chahine

机构：

[1] a patent attorney in Salt Lake City,

来源：

Nature Biotechnology | 1998年 / 16卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：132 / 132

相关论文

共 50 条

[31] Cancer survivors' perspectives on the US generic drug shortage
Nutt, Stephanie
Rechis, Ruth
Shulman, Lawrence N.
Hayes-Lattin, Brandon M.
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[32] Differences in Generic Drug Prices between the US and Canada
Gooi, Malcolm
Bell, Chaim M.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2008, 6 (01) : 19 - 26
[33] The voluntary incentive structure of pediatric exclusivity and its impacts on pharmaceutical industry behavior and generic drug entries
Rhee, J.
VALUE IN HEALTH, 2007, 10 (03) : A25 - A25
[34] Drug Discovery Market Exclusivity After KSR:The Challenge to Pharmaceutical Scientists and the US Congress
Wolff, Manfred E.
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (08) : 3044 - 3054
[35] Maximizing exclusivity for drug products
French, H
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (09) : 709 - 709
[36] Maximizing exclusivity for drug products
Hayley French
Nature Reviews Drug Discovery, 2005, 4 : 709 - 709
[37] US AGENCIES DISAGREE ON BIOSIMILAR NAMING
不详
CHEMICAL & ENGINEERING NEWS, 2015, 93 (44) : 22 - 22
[38] The Redemption of Drug Patent Linkage System: The Dilemma and Improvement in the Qualification System of Market Exclusivity Period for China's First Generic Drug
Zhang, Huaiyin
Ji, Yuqi
BIOTECHNOLOGY LAW REPORT, 2024, 43 (06) : 318 - 331
[39] Will inter partes review speed US generic drug entry?
Jonathan J Darrow
Reed F Beall
Aaron S Kesselheim
Nature Biotechnology, 2017, 35 : 1139 - 1141
[40] FDA approval of generic drugs: Instituting a first successful defense requirement for generic exclusivity
Mason, JC
BIOTECHNOLOGY LAW REPORT, 2003, 22 (02) : 97 - 108

← 1 2 3 4 5 →